CONTEXT: Sildenafil increases insulin sensitivity in mice. In humans, phosphodiesterase 5 inhibition improves disposition index, but the mechanism of this effect has not been elucidated and may depend on duration. In addition, increasing cyclic GMP without increasing nitric oxide could have beneficial effects on fibrinolytic balance. OBJECTIVE: The objective was to test the hypothesis that chronic phosphodiesterase 5 inhibition with sildenafil improves insulin sensitivity and secretion without diminishing fibrinolytic function. DESIGN: This was a randomized, double-blind, placebo-controlled study. SETTING: This trial was conducted at Vanderbilt Clinical Research Center. PARTICIPANTS: Participants included overweight individuals with prediabetes. INTERVENTIONS: Subjects were randomized to treatment with sildenafil 25 mg three times a day or matching placebo for 3 months. Subjects underwent a hyperglycemic clamp prior to and at the end of treatment. MAIN OUTCOME MEASURES: The primary outcomes of the study were insulin sensitivity and glucose-stimulated insulin secretion. RESULT: Twenty-one subjects completed each treatment arm. After 3 months, the insulin sensitivity index was significantly greater in the sildenafil group compared to the placebo group by 1.84 mg/kg/min per μU/mL*100 (95% confidence interval, 0.01 to 3.67 mg/kg/min per μU/mL*100; P = .049), after adjusting for baseline insulin sensitivity index and body mass index. In contrast, there was no effect of 3-month treatment with sildenafil on acute- or late-phase glucose-stimulated insulin secretion (P > .30). Sildenafil decreased plasminogen activator inhibitor-1 (P = .01), without altering tissue-plasminogen activator. In contrast to placebo, sildenafil also decreased the urine albumin-to-creatinine ratio from 12.67 ± 14.67 to 6.84 ± 4.86 μg/mg Cr. This effect persisted 3 months after sildenafil discontinuation. CONCLUSIONS: Three-month phosphodiesterase 5 inhibition enhances insulin sensitivity and improves markers of endothelial function.
RCT Entities:
CONTEXT: Sildenafilincreases insulin sensitivity in mice. In humans, phosphodiesterase 5 inhibition improves disposition index, but the mechanism of this effect has not been elucidated and may depend on duration. In addition, increasing cyclic GMP without increasing nitric oxide could have beneficial effects on fibrinolytic balance. OBJECTIVE: The objective was to test the hypothesis that chronic phosphodiesterase 5 inhibition with sildenafil improves insulin sensitivity and secretion without diminishing fibrinolytic function. DESIGN: This was a randomized, double-blind, placebo-controlled study. SETTING: This trial was conducted at Vanderbilt Clinical Research Center. PARTICIPANTS: Participants included overweight individuals with prediabetes. INTERVENTIONS: Subjects were randomized to treatment with sildenafil 25 mg three times a day or matching placebo for 3 months. Subjects underwent a hyperglycemic clamp prior to and at the end of treatment. MAIN OUTCOME MEASURES: The primary outcomes of the study were insulin sensitivity and glucose-stimulated insulin secretion. RESULT: Twenty-one subjects completed each treatment arm. After 3 months, the insulin sensitivity index was significantly greater in the sildenafil group compared to the placebo group by 1.84 mg/kg/min per μU/mL*100 (95% confidence interval, 0.01 to 3.67 mg/kg/min per μU/mL*100; P = .049), after adjusting for baseline insulin sensitivity index and body mass index. In contrast, there was no effect of 3-month treatment with sildenafil on acute- or late-phase glucose-stimulated insulin secretion (P > .30). Sildenafil decreased plasminogen activator inhibitor-1 (P = .01), without altering tissue-plasminogen activator. In contrast to placebo, sildenafil also decreased the urine albumin-to-creatinine ratio from 12.67 ± 14.67 to 6.84 ± 4.86 μg/mg Cr. This effect persisted 3 months after sildenafil discontinuation. CONCLUSIONS: Three-month phosphodiesterase 5 inhibition enhances insulin sensitivity and improves markers of endothelial function.
Authors: James M Luther; Loretta M Byrne; Chang Yu; Thomas J Wang; Nancy J Brown Journal: J Clin Endocrinol Metab Date: 2014-07-16 Impact factor: 5.958
Authors: William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan Journal: N Engl J Med Date: 2002-02-07 Impact factor: 91.245
Authors: Kenji Matsushita; Craig N Morrell; Beatrice Cambien; Shui Xiang Yang; Munekazu Yamakuchi; Clare Bao; Makoto R Hara; Richard A Quick; Wangsen Cao; Brian O'Rourke; John M Lowenstein; Jonathan Pevsner; Denisa D Wagner; Charles J Lowenstein Journal: Cell Date: 2003-10-17 Impact factor: 41.582
Authors: L Bergandi; F Silvagno; I Russo; C Riganti; G Anfossi; E Aldieri; D Ghigo; M Trovati; A Bosia Journal: Arterioscler Thromb Vasc Biol Date: 2003-11-13 Impact factor: 8.311
Authors: F Marampon; C Antinozzi; C Corinaldesi; G B Vannelli; E Sarchielli; S Migliaccio; L Di Luigi; A Lenzi; C Crescioli Journal: Endocrine Date: 2017-08-07 Impact factor: 3.633
Authors: Antonio Aversa; Simona Fittipaldi; Davide Francomano; Viviana M Bimonte; Emanuela A Greco; Clara Crescioli; Luigi Di Luigi; Andrea Lenzi; Silvia Migliaccio Journal: Endocrine Date: 2017-01-30 Impact factor: 3.633
Authors: Cyndya A Shibao; Jorge E Celedonio; Claudia E Ramirez; Latisha Love-Gregory; Amy C Arnold; Leena Choi; Luis E Okamoto; Alfredo Gamboa; Italo Biaggioni; Naji N Abumrad; Nada A Abumrad Journal: J Clin Endocrinol Metab Date: 2016-05-04 Impact factor: 5.958
Authors: Gail K Adler; Gillian R Murray; Adina F Turcu; Hui Nian; Chang Yu; Carmen C Solorzano; Robert Manning; Dungeng Peng; James M Luther Journal: Hypertension Date: 2020-03-16 Impact factor: 10.190